Clinical Trials

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

200 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04620187 2026-02-24

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

55 enrolled

Salivary Gland Neoplasms

NCT04325828 2026-02-13

YATAGARASU

31 enrolled 15 charts

Salivary Gland Neoplasms

NCT05075980 2026-02-13

Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study

174 enrolled

Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Lymphatic Metastasis, Mouth Neoplasms, Oropharyngeal Neoplasms, Paranasal Sinus Neoplasms, Salivary Gland Neoplasms

NCT04895735 2026-02-02

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

45 enrolled

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT05408845 2026-01-14

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

146 enrolled

Salivary Gland Neoplasms

NCT03942653 2025-12-31

Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

20 enrolled

Salivary Gland Neoplasms

NCT03172624 2025-12-18

Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

Phase 2 Completed

64 enrolled 9 charts

BreastDermatologicGastrointestinalHead & NeckSarcomaThoracic

Salivary Gland Neoplasms

NCT02576431 2025-11-12

NAVIGATE

Phase 2 Completed

215 enrolled 3 FDA

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Salivary Gland Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms

NCT05669664 2025-11-10

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

21 enrolled

Salivary Gland Neoplasms

NCT04209660 2025-10-07

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

64 enrolled

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT02628067 2025-09-22

KEYNOTE 158

EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

1,609 enrolled 5 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT06145308 2025-09-15

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

39 enrolled

Salivary Gland Neoplasms

NCT05608876 2025-08-07

A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer

15 enrolled

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Salivary Gland Neoplasms

NCT06805617 2025-07-29

I-MAC

35 enrolled

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT06923826 2025-07-25

TROP2

32 enrolled

Salivary Gland Neoplasms, Thyroid Neoplasms

NCT05010629 2025-05-31

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

35 enrolled

Carcinoma, Adenoid Cystic, Neoplasm Metastasis, Salivary Gland Neoplasms

NCT05694819 2025-05-22

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

56 enrolled

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT05074940 2025-04-10

Amivantamab in Adenoid Cystic Carcinoma

18 enrolled